These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18667446)

  • 21. Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.
    Lin CY; Tsai PH; Kandaswami CC; Chang GD; Cheng CH; Huang CJ; Lee PP; Hwang JJ; Lee MT
    Mol Cancer; 2011 Jul; 10():87. PubMed ID: 21777419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
    Wei H; Hellström KE; Hellström I
    Gynecol Oncol; 2012 Jun; 125(3):727-33. PubMed ID: 22430613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.
    Shao M; Cao L; Shen C; Satpathy M; Chelladurai B; Bigsby RM; Nakshatri H; Matei D
    Cancer Res; 2009 Dec; 69(24):9192-201. PubMed ID: 19951993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
    Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
    Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
    Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
    Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian cancer cells.
    Parajuli B; Lee HG; Kwon SH; Cha SD; Shin SJ; Lee GH; Bae I; Cho CH
    Cancer Epidemiol; 2013 Aug; 37(4):512-7. PubMed ID: 23545383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
    Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ
    Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
    Jung HJ; Chen Z; Wang M; Fayad L; Romaguera J; Kwak LW; McCarty N
    Blood; 2012 Mar; 119(11):2568-78. PubMed ID: 22294726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy.
    Zhang H; Chen Z; Miranda RN; Medeiros LJ; McCarty N
    Cancer Res; 2016 Nov; 76(21):6410-6423. PubMed ID: 27488529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
    Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
    Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
    Kumar A; Xu J; Sung B; Kumar S; Yu D; Aggarwal BB; Mehta K
    Breast Cancer Res; 2012 Jan; 14(1):R4. PubMed ID: 22225906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity.
    Satpathy M; Shao M; Emerson R; Donner DB; Matei D
    J Biol Chem; 2009 Jun; 284(23):15390-9. PubMed ID: 19324884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
    Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
    Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway.
    Mann AP; Verma A; Sethi G; Manavathi B; Wang H; Fok JY; Kunnumakkara AB; Kumar R; Aggarwal BB; Mehta K
    Cancer Res; 2006 Sep; 66(17):8788-95. PubMed ID: 16951195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
    Yang J; Li G; Zhang K
    Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.
    Dai Y; Jin S; Li X; Wang D
    Oncotarget; 2017 Jan; 8(1):1354-1368. PubMed ID: 27935869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
    Agnihotri N; Mehta K
    Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
    Meshram DD; Pike CVS; Coussons PJ
    Eur J Pharmacol; 2017 Nov; 815():332-342. PubMed ID: 28943101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.